Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Genprex (NASDAQ: GNPX) has formed a Mesothelioma Clinical Advisory Board to support its preclinical mesothelioma oncology program. The board consists of four renowned researchers specializing in mesothelioma treatment. This initiative aims to advance Genprex's Reqorsa® Gene Therapy, which uses the TUSC2 tumor suppressor gene. TUSC2 expression is downregulated in 84% of mesotheliomas, and Genprex's collaborators will present additional positive preclinical data next month at the 2024 EORTC-NCI-AACR Symposium.
Reqorsa® uses Genprex's Oncoprex® Delivery System to target cancer cells while minimizing uptake by normal tissue. Mesothelioma affects approximately 3,000 new cases annually in the U.S., with a life expectancy of 18 months for pleural mesothelioma and a 3-year survival rate of 23% with treatment.
Genprex (NASDAQ: GNPX) ha formato un Comitato Consultivo Clinico per il Mesotelioma per supportare il suo programma oncologico preclinico sul mesotelioma. Il comitato è composto da quattro rinomati ricercatori specializzati nel trattamento del mesotelioma. Questa iniziativa mira a far avanzare la Gene Therapy Reqorsa® di Genprex, che utilizza il gene soppressore tumorale TUSC2. L'espressione di TUSC2 è ridotta in 84% dei mesoteliomi, e i collaboratori di Genprex presenteranno ulteriori dati preclinici positivi il mese prossimo al Simposio EORTC-NCI-AACR 2024.
Reqorsa® utilizza il Oncoprex® Delivery System di Genprex per colpire le cellule tumorali riducendo al minimo l'assunzione da parte dei tessuti normali. Il mesotelioma colpisce circa 3.000 nuovi casi all'anno negli Stati Uniti, con un'aspettativa di vita di 18 mesi per il mesotelioma pleurico e un tasso di sopravvivenza del 23% a 3 anni con trattamento.
Genprex (NASDAQ: GNPX) ha formado un Consejo Asesor Clínico de Mesotelioma para respaldar su programa oncológico preclínico de mesotelioma. El consejo está compuesto por cuatro investigadores de renombre especializados en el tratamiento del mesotelioma. Esta iniciativa busca avanzar la Terapia Genética Reqorsa® de Genprex, que utiliza el gen supresor tumoral TUSC2. La expresión de TUSC2 está disminuida en el 84% de los mesoteliomas, y los colaboradores de Genprex presentarán datos preclínicos adicionales positivos el próximo mes en el Simposio EORTC-NCI-AACR 2024.
Reqorsa® utiliza el Sistema de Entrega Oncoprex® de Genprex para dirigirse a las células cancerosas mientras minimiza la captación por parte de tejido normal. El mesotelioma afecta aproximadamente a 3,000 nuevos casos anuales en los EE.UU., con una expectativa de vida de 18 meses para el mesotelioma pleural y una tasa de supervivencia del 23% a 3 años con tratamiento.
Genprex (NASDAQ: GNPX)는 장기적인 중피암 임상 자문 위원회를 설립하여 중피암 온콜로지 프로그램의 전임상 개선을 지원합니다. 이 위원회는 중피암 치료에 전문화된 네 명의 저명한 연구원으로 구성되어 있습니다. 이 이니셔티브는 TUSC2 종양 억제 유전자를 사용하는 Reqorsa® 유전자 요법의 발전을 목표로 합니다. TUSC2의 발현은 중피암의 84%에서 감소하며, Genprex의 협력자들은 다음 달 2024 EORTC-NCI-AACR 심포지엄에서 긍정적인 추가 전임상 데이터를 발표할 예정입니다.
Reqorsa®는 Oncoprex® 전달 시스템을 사용하여 정상 조직의 섭취를 최소화하면서 암 세포를 표적으로 합니다. 중피암은 미국에서 매년 약 3,000개의 새로운 사례에 영향을 미치며, 흉막 중피암의 평균 기대 수명은 18개월이고 치료를 받은 경우 3년 생존율은 23%입니다.
Genprex (NASDAQ: GNPX) a formé un Conseil Consultatif Clinique sur le Mésothéliome pour soutenir son programme d'oncologie préclinique sur le mésothéliome. Le conseil se compose de quatre chercheurs renommés spécialisés dans le traitement du mésothéliome. Cette initiative vise à faire progresser la Thérapie Génique Reqorsa® de Genprex, qui utilise le gène suppresseur de tumeur TUSC2. L'expression de TUSC2 est diminuée dans 84% des mésothéliomes, et les collaborateurs de Genprex présenteront des données précliniques supplémentaires positives le mois prochain lors du Symposium EORTC-NCI-AACR 2024.
Reqorsa® utilise le Système de Livraison Oncoprex® de Genprex pour cibler les cellules cancéreuses tout en minimisant l'absorption par les tissus normaux. Le mésothéliome touche environ 3 000 nouveaux cas chaque année aux États-Unis, avec une espérance de vie de 18 mois pour le mésothéliome pleural et un taux de survie de 23% à trois ans avec traitement.
Genprex (NASDAQ: GNPX) hat ein Beratungsgremium für klinische Studien zu Mesotheliom gegründet, um sein präklinisches Onkologieprogramm für Mesotheliom zu unterstützen. Das Gremium besteht aus vier renommierten Forschern, die auf die Behandlung von Mesotheliom spezialisiert sind. Diese Initiative zielt darauf ab, die Reqorsa® Gentherapie von Genprex voranzubringen, die das TUSC2 Tumorsuppressorgen verwendet. Die TUSC2-Expression ist bei 84% der Mesotheliome herabreguliert, und die Mitarbeiter von Genprex werden nächsten Monat auf dem 2024 EORTC-NCI-AACR-Symposium zusätzliche positive präklinische Daten präsentieren.
Reqorsa® nutzt das Oncoprex®-Lieferungssystem von Genprex, um Krebszellen gezielt anzugreifen und gleichzeitig die Aufnahme durch normales Gewebe zu minimieren. Mesotheliom betrifft jährlich etwa 3.000 neue Fälle in den USA, mit einer Lebenserwartung von 18 Monaten für das pleurale Mesotheliom und einer 3-Jahres-Überlebensrate von 23% mit Behandlung.
- Formation of a Mesothelioma Clinical Advisory Board with renowned experts
- Positive preclinical data on TUSC2 for mesothelioma treatment to be presented
- Reqorsa® Gene Therapy shows 10 to 33 times higher uptake in tumor cells compared to normal cells
- None.
Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma
"We continue to develop a robust research program around our Reqorsa® Gene Therapy to expand its potential benefit to new patient populations, and we are pleased to assemble a group of highly respected physicians to assist in advancing our preclinical program in mesothelioma," said Ryan Confer, President and Chief Executive Officer at Genprex. "This group of world class researchers will not only provide advice and input to assist the Genprex team in moving forward our potentially promising program in mesothelioma, but the formation of this board underscores our continuous efforts to advance our research programs in some of the most difficult to treat cancers with patients who have limited treatment options or an unmet medical need."
Expression of TUSC2 is downregulated in
According to the Center for Disease Control, mesothelioma is a cancer that forms in the thin tissue that lines many internal organs, called the mesothelium. The most common kind of mesothelioma forms in the tissue around the lungs, called the pleura. This is called pleural mesothelioma, which accounts for 80
About Reqorsa® Gene Therapy
REQORSA (quaratusugene ozeplasmid) for NSCLC and small-cell lung cancer (SCLC) consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (Genprex's ONCOPREX® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells.
Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment in mesothelioma; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-formation-of-mesothelioma-clinical-advisory-board-302252784.html
SOURCE Genprex, Inc.
FAQ
What is the purpose of Genprex's new Mesothelioma Clinical Advisory Board?
How does Genprex's Reqorsa® Gene Therapy work for mesothelioma?
When will Genprex (GNPX) present new preclinical data on TUSC2 for mesothelioma treatment?
What are the current statistics for mesothelioma in the United States?
